



(51) International Patent Classification:

A61K 31/33 (2006.01) *C07K 16/30* (2006.01)
A61K 51/10 (2006.01) *A61P 43/00* (2006.01)
A61K 45/06 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2021/061180

(22) International Filing Date:

30 November 2021 (30.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/119,359 30 November 2020 (30.11.2020) US

(71) Applicant: **CORNELL UNIVERSITY** [US/US]; Center
For Technology Licensing ("CTL") at, Cornell University,
395 Pine Tree Road, Suite 310, Ithaca, NY 14850 (US).

(72) Inventors: **BANDER, Neil, H.**; 6 Old Oak Lane, PO
Box 944, Quogue, NY 11959 (US). **LECONET, Wilhelm**;
Arthur van Schendelstraat 747, 3511 MZ Utrecht (NL).

GUO, Ming; 23 Elm Street, Tenafly, NJ 07670 (US). **LIU, He**; 450 East 63rd Street, 7N, New York, NY 10065 (US).
LORENZ, Ivo; 150 Myrtle Avenue, Apt 3003, Brooklyn,
NY 11201 (US). **KHAN, Abdul, G.**; 13010 Ridgeline Blvd,
Apt 2206, Cedar Park, TX 78613 (US).

(74) Agent: **GOLDMAN, Michael, L.** et al.; Troutman Pepper
Hamilton Sanders LLP, 70 Linden Oaks, Suite 210,
Rochester, NY 14625 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION

Strict acceptor substrate specificity of glycosyltransferases




FIG. 1

(57) Abstract: The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

07 July 2022 (07.07.2022)